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INTRODUCTION
Nasal polyposis (NP) is a chronic inflammatory disease of
the upper airway featuring inflammatory cell infiltration, tis-
sue remodeling that includes extracellular matrix (ECM) accu-
mulation and fibrosis (1). The inflammatory cellular infiltrate
in nasal polyps has been shown to consist of eosinophils, lym-
phocytes, plasma cells, and mast cells to an extent which is
similar to that observed in the bronchial mucosa of asthmat-
ics (2-4), suggesting that inflammatory mechanisms of the
two diseases may be similar (5). According to experimental
models, it seems reasonable to speculate that the formation
and growth of NPs require ECM accumulation (6).
The matrix metalloproteinases (MMPs) appear to be respon-
sible for edema and cell transmigration, and ECM remodeling
in asthmatic airways (7). Among the matrix metalloprotein-
ases (MMPs), MMP-9, especially active MMP-9 expression,
was clearly enhanced in nasal polyps compared with control
mucosa (8). The activation of MMPs is inhibited by tissue
inhibitors of metalloproteinases (TIMPs) that form a 1:1
complex with MMPs (9). Loss of coordination in the expres-
sion of MMPs and TIMPs is believed to generate tissue degra-
dation in inflammatory diseases. Eosinophil is one of the major
sources of MMPs; MMP-9 was overexpressed by eosinophils
accumulating in airway walls of asthmatics (10). Several in
vitro studies have demonstrated that MMP-2 and MMP-9
were produced and activated by mast cells, and the possible
involvement of mast cells in connective tissue degradation
and fibrosis was suggested (11, 12).
Transforming growth factor- (TGF- ) is a chemoattrac-
tant for fibroblasts, stimulating fibroblast proliferation, and
enhancing collagen laydown by fibroblasts. Of the TGF-
isoforms, TGF- 1 synthesized by infiltrating eosinophils may
contribute to stromal fibrosis and basement membrane thick-
ening which are characteristic of nasal polyp (13). Another in
vitro study showed that TGF- 1 induces MMP-9 proenzyme
and MMP-2 (14). There have been few studies in relation to
infiltrating cell activations and TGF- 1 on the specific effects
of MMP-2, MMP-9, and TIMP-1 in nasal polyps, which sh-
ares certain similarities with asthma. The aim of the present
study was to investigate the association between MMPs and
TIMP-1, and inflammatory cell activation markers in nasal
polyp tissue in relation to TGF- 1.
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Eosinophil Inflammation of Nasal Polyp Tissue: Relationships with
Matrix Metalloproteinases, Tissue Inhibitor of Metalloproteinase-1, and
Transforming Growth Factor- 1
Eosinophil and mast cell infiltrations are consistent findings in nasal polyp tissue. Pre-
vious studies have shown that matrix metalloproteinases (MMPs) may be involved
in eosinophil infiltration in airway mucosa of asthmatic patients, and that transforming
growth factor-beta1 (TGF- 1) induces extracellular matrix deposition in nasal polyp
tissue. The aim of this study was to evaluate the role of MMPs and tissue-inhibitor
of metalloproteinase-1 (TIMP-1) in association with TGF- 1, eosinophils and mast
cell activation in nasal polyp tissue. Nasal polyp tissues from 20 patients who under-
went polypectomies were collected and prepared into tissue homogenate. Eosinophil
cationic protein (ECP) and tryptase levels were measured by CAP system (Pharma-
cia, Sweden). MMP-2, MMP-9, TIMP-1 and TGF- 1 levels were measured by en-
zyme-liked immunosorbent assay. MMP-2 was the predominant form of MMPs, fol-
lowed by MMP-9 and TIMP-1. There were significant correlations between ECP, and
MMP-9, MMP-2, TGF- 1 and tryptase, but not with TIMP-1. Significant correlations
were noted between tryptase, and MMP-2, MMP-9, and TGF- 1, but not with TIMP-
1. Close correlations were noted between TGF- 1, and MMP-9 and MMP-2, but not
with TIMP-1. MMP-2, MMP-9, and TGF- 1 may contribute to eosinophil and mast
cell migrations into nasal polyp tissue.
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MATERIALS AND METHODS
Subjects
Nasal polyps were obtained from 20 patients with bronchial
asthma, between the ages of 27 and 56 yr (40.0±3.4 yr [mean
±SEM]), who had complained of asthmatic symptoms dur-
ing visits to the Allergy Clinic of Ajou University Hospital,
Suwon, Korea (Table 1). Nasal polyps were identified by ante-
rior rhinoscopy in all patients. Asthma was diagnosed accord-
ing to the American Thoracic Society guidelines for the diag-
nosis of asthma (15). Skin prick test with common aeroaller-
gens (Bencard, U.K.) was performed and atopy was defined
as showing positive response (≥3+ by Allergen/Histamine
ratio) to two or more inhalant allergens. None of the study
subjects had used topical steroids for at least 4 weeks prior to
obtaining the polyp. The polyps, soon after surgical removal,
were washed with normal saline to remove stagnant mucus.
The middle portion of the polyp was cut off and immediately
sent to a pathology laboratory to prepare the paraffin-embed-
ded tissue. Half of them were made into tissue homogenate.
All the subjects gave their informed consent as regulated by
the Ajou University Hospital, Suwon, Korea. 
Preparation of nasal polyp tissue
The polyp tissue was frozen at -70℃ immediately after the
operation. When prepared for the experiments, the samples
were thawed, and ground in a homogenizer (POLYTRON,
Switzerland) with phosphate-buffered saline (PBS, pH7.5)
including 1% Triton X-100. They were centrifuged and the
separated supernatant was kept at -70℃to measure ECP, tryp-
tase, MMP-2, MMP-9, TIMP-1, and TGF- 1 levels.
Enzyme-Linked Immunosorbent Assays for MMP-2,
MMP-9, TIMP-1, and TGF- 1
Commercially available kits were used (MMP-2, MMP-9,
and TIMP-1:RPN 2617, RPN 2614, and RPN 2611, respec-
tively; Amersham Pharmacia Bioteck, U.K., TGF- 1:Quan-
tikine; R&D Systems, Minneapolis, U.S.A.). The MMP-2 and
MMP-9 ELISA detects free proMMP-2, proMMP-9, and pro
MMP-9-TIMP-1 complexes. It does not detect active MMP-
2 or MMP-9. The TIMP-1 kit detects the total TIMP-1, free
TIMP-1, and MMP-9-TIMP-1 complexes. For all assays, opti-
cal density was measured with a spectrophotometer set at 450
nm. Quantification was performed by interpolation from a
standard curve. The detection limit was 0.37 ng/mL for MMP-
2, 0.6 ng/mL for MMP-9, 1.25 ng/mL for TIMP-1, and 7 pg/
mL for TGF- 1. 
Levels of protein were also measured by nephelometry (16)
with a Beckman Array system (Beckman Instruments Inc.,
Brea, Calif). The data of MMPs, TIMP-1, and TGF- 1 con-
centrations in tissue homogenate of nasal polyp were present-
ed as the ratio of protein measured, and were expressed as ng/
mg protein concentration.
ECP and tryptase assay
ECP and tryptase in tissue homogenate of nasal polyp were
measured by fluoroimmunoassay using the Pharmacia CAP
system (Pharmacia and Upjohn, Uppsala, Sweden). The low-
est detection limits for ECP and tryptase measurements were
2 ng/mL and 4 ng/mL, repectively. The data of ECP and try-
ptase concentrations were presented as the ratio of protein mea-
sured, and were expressed as ng/mg protein concentration.
Statistical analysis
The Mann-Whitney U test and ANOVA were applied us-
ing the SPSS version 7.0 (Chicago, U.S.A.) to evaluate the sta-
tistical differences among the data. The Pearson correlation
analysis was applied to evaluate the statistical significance be-
tween the two values. A p value of 0.05 or less was regarded
as significant.
RESULTS
Clinical features of the study subjects
The characteristics of the study subjects are shown in Table
1. No significant differences were noted in MMP-2, MMP-9,
TIMP-1, TGF- 1 levels, and in molar ratio of MMP-9/TIMP-
1 according to atopy status, duration of nasal symptom, and
recurrence (p>0.05, respectively).
Correlations of MMP-2, MMP-9, and TIMP-1 levels,
and inflammatory cell markers
The MMP-2 level (109.3±17.9 ng/mg protein [mean±
SEM]) was the highest in polyp tissue homogenate, followed
by the MMP-9 (40.8±11.1) and TIMP-1 (26.9±7.2) levels
(p<0.05). However, there was no significant difference between
MMP-9 and TIMP-1 levels (p>0.05; Fig. 1A). The MMP-9
level in polyp tissue homogenate was significantly correlated
with the TIMP-1 level (r=0.44, p<0.05; Fig. 1B). The ECP
level in polyp tissue homogenate was significantly correlated *Values are mean±S.E.
Number 20
Sex (male:female) 14:6
Age (yr)* 40.0±3.4
Atopy (presence/absence) 6/14
Duration of nasal symptom (yr)* 2.8±0.4
Recurrence (presence/absence) 8/12
Table 1. Characteristics of study subjectswith the MMP-2 (r=0.61, p<0.05) and MMP-9 (r=0.65, p<
0.05) levels, but not with the TIMP-1 level (r=0.42, p>0.05)
as shown in Fig. 2. Significant correlations were noted between
the tryptase level in polyp tissue homogenate, and MMP-2
(r=0.47, p<0.05), and MMP-9 (r=0.62, p<0.05), but not with
TIMP-1 (r=0.04, p>0.05) level as shown in Fig. 3.
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Fig. 1. Comparison of MMP-2, MMP-9, and TIMP-1 levels in nasal polyp tissue homogenate (A) and the correlation between MMP-9 and
TIMP-1 level (B). Horizontal bars represent mean values.
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Fig. 2. Correlations between ECP, and MMP-2 (A), MMP-9 (B) and TIMP-1 (C) levels in nasal polyp tissue.
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Fig. 3. Correlations between tryptase, and MMP-2 (A), MMP-9 (B) and TIMP-1 (C) levels in nasal polyp tissue.
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Correlations of TGF- 1, MMPs, and TIMP-1 levels, and
inflammatory cell markers
As shown in Fig. 4, close correlations were also noted bet-
ween the TGF- 1 level in polyp tissue homogenate, and the
MMP-2 (r=0.82, p<0.05) and MMP-9 (r=0.92, p<0.05) levels,
but not with the TIMP-1 level (r=0.31, p>0.05). Fig. 5 shows
the correlations between the ECP, tryptase, and TGF- 1 levels.
The ECP level in polyp tissue homogenate was significantly cor-
related with the tryptase (r=0.58, p<0.05; Fig. 5A) and TGF-
1 levels (r=0.62, p<0.05; Fig. 5C). Tryptase was significant-
ly correlated with the TGF- 1 level (r=0.73, p<0.05; Fig. 5B).
DISCUSSION
Inflammatory processes within the mucosa of the upper res-
piratory tract are believed to play an important role in the devel-
opment of nasal polyp. Nasal mucosa infiltration by numerous
eosinophils and mast cells is the most characteristic feature of
nasal polyposis (17). Higher ECP and eosinophil counts were
noted in patients with polyposis, suggesting that an excessive
response by activated eosinophils may induce a more profound
inflammatory process of the nasal polyp (18). Mast cells act
as a key effector in allergic reactions with an ability to release
both tryptase and cytokines in response to allergen (19). Nasal
polyp has tryptase-containing mast cells in both epithelial and
stromal layers, suggesting that activated mast cells which de-
granulate and release tryptase could participate in nasal polyp
generation (17). Another previous study demonstrated that
activated mast cells induced the release of eosinophil cationic
protein (20). In this study, tryptase was detected and signif-
icantly correlated with ECP in nasal polyp tissue, which was
responsible for chronic inflammatory response of nasal polyps.
A previous study demonstrated the presence of elevated lev-
els of pro- and active form of MMP-9 in nasal polyps by im-
munohistochemistry and zymography, while MMP-2 expres-
sion remained almost equivalent to both nasal polyp tissue
and control mucosa (8). In this study, however, MMP-2 was
the predominant form of MMPs in nasal polyp tissue, followed
by MMP-9. MMP-9 was reported in an in vitro system to play
a crucial role in the transmigration of eosinophils (21), and to
be overexpressed by eosinophils accumulating in airway walls
of asthmatics (10). After eosinophils migrated to nasal mucosa
Fig. 5. Correlations between ECP and tryptase (A), TGF- 1 and tryptase (B), and ECP and TGF- 1 (C) levels in nasal polyp tissue.
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Fig. 4. Correlations between TGF- 1, and MMP-2 (A), MMP-9 (B) and TIMP-1 (C) level in nasal polyp tissue.
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A B Cby their own MMP-2 and -9, they would trigger the synthe-
sis of MMP-2 and -9, which may be involved in the develop-
ment and maintenance of airway inflammation in asthmat-
ics. Tryptase, which is the specific and major enzyme of human
mast cell granules (22), degrades fibronectin and cleaves pro
MMP-2 to the activated form (23). Recently, an in vitro study
demonstrated that human cultured mast cells could express
MMP-9 (11). As shown in the previous study (11, 23), mast
cells localized in nasal mucosa expressed MMP-2 and MMP-
9 in pathological condition and these findings support the view
that the mast cells may influence ECM degradation and remo-
deling in allergic inflammation. In this study, MMP-2 and
MMP-9 were significantly correlated with ECP as well as tryp-
tase, which suggests the possibility that MMP-2 and MMP-9
may be involved in migration of eosinophils and mast cells
into nasal polyp tissue. This data also suggests that mast cells
and eosinophils might be, either directly or indirectly, respon-
sible for the production of MMPs. MMP-2 may not only be
synthesized abundantly in inflamed nasal mucosa, whether
they are pro- or active form, but it may also play a role in nasal
polyp formation and growth.
Recently, MMP-9 and TIMP-1 expressions were reported in
the epithelial cells of nasal mucosa and infiltrating eosinophils
as well as bronchial tissue in asthmatics (7, 24, 25). The above
data demonstrated that the extent of MMP-9 expression was
greater than that of TIMP-1. Moreover, MMP-9 expression
significantly correlated with eosinophil infiltration in nasal
mucosa. In healthy subjects, MMP-9 was co-secreted with
TIMP-1 in 1:1 stoichiometry, and previous reports showed the
imbalance between MMP-9 and TIMP-1 in airway inflam-
mation (25, 26). In this study, the MMP-9 level was higher
than the TIMP-1 level and significantly correlated with the
TIMP-1 level. However, the TIMP-1 level or the molar ratio
of MMP-9/TIMP-1 was not different according to clinical para-
meters, and it was not correlated with cellular activation
markers. This result suggests that TIMP-1 is co-secreted with
MMP-9 in nasal polyp tissue, and the MMP-9/TIMP-1 imbal-
ance may play a role in regulating inflammatory response in
nasal polyp tissue.
Recent studies demonstrated that TGF- 1 was strongly
expressed in inflammatory nasal mucosa and allergic rhinitis
tissues but not in normal nasal mucosa, and also found that
eosinophils represented a major source of TGF- 1 in nasal
polyp tissue (13, 27). Recently, Sehgal and Thompson (14) found
that TGF- 1 stimulates the MMP-2 and MMP-9 secretory
activity in human prostate cell lines. Another in vitro study
showed that MMP-9, as well as MMP-2, proteolytically cleave
latent TGF- , providing a novel and potentially important
mecha-nism for TGF- activation (28). Furthermore, in pati-
ents with chronic airway inflammation, TGF- 1 correlated
with the number of macrophage and mast cells in bronchio-
lar epithelium (29). In nasal polyposis, especially mature nasal
polyp, mast cells are more abundant in the submucosa, and
they degranulate in human mature nasal polyps (30). Our data
also showed that the TGF- 1 level in nasal polyp tissue was
significantly correlated with MMP-2, MMP-9, ECP, and tryp-
tase. According to the above results, we suggest the hypothesis
that TGF- 1, in conjunction with MMP-2 and MMP-9, might
be involved in ECM degradation and fibrosis in nasal polyp
tissue where eosinophils and mast cells are the most prevalent
cells.
In conclusion, this study has identified the presence of MMP-
2, MMP-9, and TGF- 1 in nasal polyp tissue in relation to
eosinophil and mast cell activation. Both MMP-2 and MMP-
9 may play a role in migration of eosinophils and mast cells
into nasal polyp tissue. Further studies will be needed to elu-
cidate the role of TGF- 1 in nasal polyp inflammation.
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